A promising treatment combination has emerged for patients with a common type of non-Hodgkin lymphoma, offering hope for improved outcomes. But is it a game-changer or a controversial approach?
The Latest Findings:
Recent updates from the EPCORE NHL-2 trial presented at ASH 2025 reveal encouraging results for epcoritamab, a novel therapy, when combined with chemotherapy in treating newly diagnosed diffuse large B-cell lymphoma (DLBCL). This combination therapy demonstrated remarkable response rates and remissions, especially in high-risk and older patients.
The Study Details:
In this phase 2 trial, researchers enrolled adults with CD20-positive DLBCL who were not candidates for full-dose R-CHOP chemotherapy due to age or comorbidities. Participants received epcoritamab, a subcutaneous medication, alongside a modified chemotherapy regimen, R-mini-CHOP. The treatment schedule varied in frequency over several cycles, with a step-up dosing strategy.
Impressive Results:
The overall response rate (ORR) was an impressive 89%, with a complete response (CR) rate of 86%. Even more striking, the 2-year progression-free survival (PFS) and overall survival (OS) rates were 76% and 82%, respectively. Minimal residual disease (MRD) negativity, a crucial marker for long-term outcomes, was achieved in 95% of evaluable patients, including those with high-risk features. And here's where it gets controversial: the study reported a 29% rate of grade 3 or higher infections, and 11% of patients discontinued treatment due to adverse events.
A Second Analysis:
In a separate analysis, patients received epcoritamab with standard R-CHOP chemotherapy for 6 cycles, followed by epcoritamab monotherapy. This approach also yielded impressive results, with an ORR of 98% and a CR rate of 85%. These responses were sustained in the majority of patients, regardless of risk factors. The study assessed MRD negativity and found similar promising results.
Controversy and Promise:
While the combination of epcoritamab and chemotherapy shows immense potential, the high infection rates and treatment discontinuations due to adverse events raise important questions. Could this treatment be too aggressive for some patients? How can we balance efficacy and safety? These are crucial considerations as we strive to provide the best care for DLBCL patients.
What are your thoughts on this promising yet controversial treatment approach? Do the benefits outweigh the risks? Share your opinions and let's spark a thoughtful discussion!
